AZD2287

BIOLOGICAL2 trials

Sponsors

AstraZeneca

Conditions

Metastatic Castration-Resistant Prostate CancerMetastatic Prostate Cancer

Phase 1

Study of AZD0754 in Participants With Metastatic Prostate Cancer

RecruitingNCT06267729

AstraZenecaMetastatic Prostate Cancer

Start: 2024-03-12End: 2026-11-24Target: 60Updated: 2026-02-23

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT06879041

AstraZenecaMetastatic Castration-Resistant Prostate Cancer

Start: 2025-03-10End: 2029-04-16Target: 136Updated: 2026-05-12